According to the latest research by Persistence Market Research, the vulvar and vaginal atrophy therapy market is set to witness 11.5% growth during 2021-2031.
Growing healthcare investment for early detection of infectious diseases, complications related to pregnancy, increasing number of patients with genitourinary symptoms, menopausal loss of estrogen, and launch of new and effective VVA therapy is likely to further drive the global vulvar and vaginal atrophy therapy market.
According to the National Center for Biotechnology Information (NCBI), Vulvar and vaginal atrophy (VVA) is a frequent condition that impacts women after menopause, however, it is not always symptomatic. The vaginal epithelium thins, vaginal blood flow declines, and vaginal lubrication decrease as estrogen levels decline throughout menopause.
Changes in the resident flora, such as a decrease in acid-producing bacteria and an increase in vaginal pH, are also noticeable. Dryness, vulva discomfort, burning sensations, and other symptoms are frequently observed.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32923
Leading vulvar and vaginal atrophy therapy market manufacturers are currently using technologically advanced production techniques to improve product efficacy. The present growth prospects in the industry have also been investigated by looking at the continuing process development of top firms to analyse their market position and assist readers in formulating profitable partnership, expansion, and collaboration strategies.
Some of the leading manufacturers and suppliers of vulvar and vaginal atrophy therapy market include
- Almirall
- VenusConcept
- Alma Lasers
- ThermiGen LLC
- Lutronic
- BTL Group of Companies
- Viveve
- Fotona
- Hologic
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32923
Growth in vulvar and vaginal atrophy therapy is likely to be fueled by rising cases of genitourinary syndrome of menopause, rising demand for vulvar vaginal atrophy therapy, raising awareness among the patients VVA therapy, changing lifestyle, greater disposable income, and increased awareness of the different treatment choices available.
Furthermore, the market is expected to be fueled by increased awareness of aesthetic procedures, particularly female cosmetic genital surgery.
The market for vulvar and vaginal atrophy therapy market is most prominently driven by countries like U.S and Canada. The rising cases of genitourinary syndrome of menopause which includes genital symptoms like dryness, burning and irritation, lack of lubrication, pain and discomfort in sexual intercourse, growing awareness on VVA therapy, new product launch, and presence of major market players are the major factors that are boosting the growth of the VVA therapy market demand in the US and Canada.
Europe is one of the leading markets in the vulvar and vaginal atrophy therapy market due to the rising demand for vulvar vaginal atrophy therapy (VVA). Other important drivers supporting the growth of the market include an increasing number of surgeons in the region, consumer buying power, well-established health care infrastructure, and research activity in the industry.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/32923
In addition rising awareness of vulvar and vaginal atrophy therapy (VVA) and increasing acceptance of modern technologies are likely to boost demand.
The Asia Pacific is likely to expect the highest growth during the forecast period. Rising number of patients with VVA symptoms, rising awareness on VVA therapy, and growing healthcare spending to dominate the global market for vulvar and vaginal atrophy therapy in the Asia Pacific.
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com